Description
Bevastim 100 MG & 400 MG (Bevacizumab) is a recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds to and neutralizes vascular endothelial growth factor A (VEGF-A) a targeted anti-angiogenic biologic agent that prevents VEGF-A from binding to its receptors (VEGFR-1/Flt-1 and VEGFR-2/KDR/Flk-1) on the surface of vascular endothelial cells, thereby inhibiting receptor-mediated downstream signaling cascades (including PI3K-AKT and RAS-MAPK pathways) that drive tumor-induced angiogenesis, neovascularization, and vascular permeability, suppressing the formation and maintenance of the tumor-associated vasculature required for tumor growth, invasion, and metastatic dissemination supplied as a concentrated solution for intravenous (IV) infusion in two strengths: 100 mg/4 mL (25 mg/mL) and 400 mg/16 mL (25 mg/mL), 1 vial per box, and manufactured by Beacon Pharmaceuticals PLC, Bangladesh.
Bevacizumab, the active pharmaceutical ingredient of Bevastim, is an anti-VEGF therapy approved for multiple solid tumor indications, including metastatic colorectal cancer (mCRC) in combination with intravenous fluoropyrimidine-based chemotherapy for first- or second-line treatment, and epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel (followed by single-agent bevacizumab) for Stage III or IV disease following initial surgical resection establishing bevacizumab as the first FDA-approved anti-angiogenic therapy and one of the most broadly indicated oncology biologics in clinical practice.
The recommended dose and schedule of Bevastim (Bevacizumab) are indication- and regimen-dependent: for first-line metastatic colorectal cancer (mCRC) in combination with bolus-IFL, the recommended dose is 5 mg/kg IV every 2 weeks; for mCRC in combination with FOLFOX4 (second-line), the recommended dose is 10 mg/kg IV every 2 weeks; for Stage III/IV epithelial ovarian cancer (first-line, following initial surgical resection), the recommended dose is 15 mg/kg IV every 3 weeks in combination with carboplatin and paclitaxel for up to 6 cycles, followed by bevacizumab 15 mg/kg every 3 weeks as single-agent maintenance until disease progression or unacceptable toxicity; bevacizumab must be administered as an IV infusion only never as IV push or bolus; the initial infusion is delivered over 90 minutes; if well tolerated, the second infusion may be administered over 60 minutes; subsequent infusions may be delivered over 30 minutes if the 60-minute infusion is well tolerated.
The pivotal Phase III first-line mCRC registration trial (Study AVF2107g; NCT00109070) evaluated bevacizumab 5 mg/kg IV every 2 weeks plus bolus-IFL versus placebo plus bolus-IFL in 813 patients with previously untreated metastatic colorectal cancer, achieving a statistically significant improvement in the primary endpoint of median overall survival (OS) of 20.3 months in the bevacizumab arm versus 15.6 months in the control arm (HR 0.66; 95% CI, 0.54–0.81; p<0.001), with a median progression-free survival (PFS) of 10.6 months versus 6.2 months (HR 0.54; 95% CI, 0.45–0.66; p<0.001), and an overall response rate (ORR) of 45% versus 35% (p<0.01), establishing bevacizumab as the first anti-angiogenic therapy to demonstrate a survival benefit in metastatic colorectal cancer.
Important: The most clinically significant adverse reactions of bevacizumab are gastrointestinal (GI) perforation, wound healing complications, severe hemorrhage, arterial thromboembolic events (ATEs), venous thromboembolic events (VTEs), hypertensive crisis, nephrotic syndrome, and reversible posterior leukoencephalopathy syndrome (RPLS). Bevacizumab must not be initiated until at least 28 days following major surgery and until the surgical incision has fully healed; bevacizumab should be permanently discontinued in patients who develop GI perforation or fistula, severe bleeding, hypertensive crisis, nephrotic syndrome, or RPLS.
Blood pressure must be monitored every 2–3 weeks during treatment; antihypertensive therapy should be initiated for bevacizumab-associated hypertension; withhold bevacizumab for uncontrolled hypertension. Urine protein should be monitored by dipstick urinalysis before each infusion; withhold bevacizumab for proteinuria ≥2+ on dipstick urinalysis and monitor 24-hour urine protein; permanently discontinue for proteinuria >3.5 g/24 hours (nephrotic syndrome). Screen for arterial thromboembolic events (stroke, transient ischemic attack, myocardial infarction, angina) throughout treatment; permanently discontinue bevacizumab for any ATE.
Ovarian failure has been reported in premenopausal women receiving bevacizumab; prior to initiating therapy, inform premenopausal women of the potential risk of premature ovarian failure and its impact on fertility. Do not substitute Bevastim for other bevacizumab biosimilars or for ramucirumab, aflibercept, or other anti-angiogenic agents without confirmed indication-specific prescribing and clinical benefit-risk assessment by the treating oncologist. Searching for Bevastim 100 MG 400 MG Bevacizumab? Mediaid Pharmacy lists this product across its oncology medicines, colorectal cancer medicines, ovarian cancer medicines, and Beacon Pharmaceuticals medicines portfolios and ships it worldwide.
Basic Product Information of Bevastim 100 MG & 400 MG (Bevacizumab)
| Brand Name | Bevastim 100 MG & 400 MG (Bevacizumab) Bangladesh-manufactured by Beacon Pharmaceuticals PLC; bevacizumab is also marketed internationally as Avastin (bevacizumab) by Roche/Genentech in the United States and global markets; Bevastim is the branded generic/biosimilar formulation of bevacizumab concentrated solution for IV infusion manufactured by Beacon Pharmaceuticals PLC for the domestic and international oncology market |
| Product Name | Bevastim (branded bevacizumab concentrated solution for IV infusion, 100 mg/4 mL and 400 mg/16 mL, by Beacon Pharmaceuticals PLC, Bangladesh) |
| Generic Name | Bevacizumab (INN; recombinant humanized immunoglobulin G1 [IgG1] monoclonal antibody directed against human VEGF-A [vascular endothelial growth factor A]; bevacizumab is composed of 93% human and 7% murine antibody sequences; it contains two antigen-binding (Fab) regions and one crystallizable (Fc) region; bevacizumab binds VEGF-A with high affinity and prevents interaction with VEGFR-1 [Flt-1] and VEGFR-2 [KDR/Flk-1] on endothelial cells, blocking VEGF-driven downstream signaling including PI3K-AKT and MAPK pathways, thereby inhibiting tumor-induced angiogenesis and neovascularization; in nonclinical xenograft models, bevacizumab caused regression of tumor vasculature, normalized remaining tumor vasculature, and inhibited new blood vessel formation; bevacizumab was originally developed by Genentech [a member of the Roche Group] from the murine anti-VEGF monoclonal antibody A.4.6.1; FDA initial approval for metastatic colorectal cancer: February 26, 2004; subsequently approved for multiple additional oncology indications including NSCLC, glioblastoma, mRCC, cervical cancer, ovarian/fallopian tube/primary peritoneal cancer) |
| Drug Class | Anti-VEGF (Anti-Vascular Endothelial Growth Factor) Monoclonal Antibody; Recombinant Humanized IgG1 Anti-Angiogenic Biologic; VEGF-A Neutralizing Antibody; Angiogenesis Inhibitor; Anti-Angiogenic Targeted Oncology Biologic; Metastatic Colorectal Cancer Anti-Angiogenic Therapy; Ovarian Cancer Anti-Angiogenic Targeted Therapy; RAS-MAPK and PI3K-AKT Pathway Downstream Suppressor (via VEGFR blockade); IV-Administered Oncology Biologic Agent; Anti-Tumor Vasculature Targeted Therapy; Multi-Indication Anti-Angiogenic Cancer Biologic |
| Formulation | Concentrated solution for intravenous (IV) infusion aseptically withdraw the necessary amount and dilute in a total volume of 100 mL 0.9% normal saline (NS) only; do not dilute in dextrose (glucose) solutions; do not administer as IV push or bolus; administer only as a slow IV infusion under close medical supervision; first infusion: administer over 90 minutes; second infusion: if first infusion is well tolerated, administer over 60 minutes; subsequent infusions: administer over 30 minutes if the 60-minute infusion is well tolerated; decrease infusion rate in case of infusion-related reactions; discontinue and administer medical therapy for severe infusion reactions; diluted solutions for infusion may be stored at 2–8°C for up to 8 hours; do not freeze or shake the vial; store undiluted vials at 2–8°C (36–46°F) in original packaging and protect from light; do not administer together with or mixed in the same IV bag with dextrose solutions; bevacizumab should be administered only by healthcare providers in a clinical setting equipped for the management of infusion reactions and anaphylaxis |
| Available Strengths | 100 mg/4 mL (25 mg/mL) per vial and 400 mg/16 mL (25 mg/mL) per vial bevacizumab dosing is weight-based (mg/kg) and varies by indication and chemotherapy regimen; the 100 mg and 400 mg vial strengths allow precise dose preparation across the full range of clinical dosing schedules: 5 mg/kg every 2 weeks (mCRC with bolus-IFL, first-line), 10 mg/kg every 2 weeks (mCRC with FOLFOX4, second-line; platinum-resistant ovarian cancer with chemotherapy), and 15 mg/kg every 3 weeks (Stage III/IV ovarian cancer, first-line, with carboplatin and paclitaxel; cervical cancer with chemotherapy); for a 70 kg patient, the 5 mg/kg dose = 350 mg per infusion cycle; the 10 mg/kg dose = 700 mg per infusion cycle; the 15 mg/kg dose = 1,050 mg per infusion cycle; institutional pharmacy teams typically combine vials to prepare the required dose per patient weight; no dose reduction schedule is defined for bevacizumab dose reductions are not recommended during clinical trials; treatment withholding, interruption, and permanent discontinuation criteria apply per NCI CTCAE version 5.0 guidance for bevacizumab-associated toxicities |
| Available Pack Size | 1 vial per box (single-dose sterile glass vial); Bevastim 100 MG: 1 vial of bevacizumab 100 mg in 4 mL concentrated solution per box; Bevastim 400 MG: 1 vial of bevacizumab 400 mg in 16 mL concentrated solution per box; institutional oncology departments, infusion centers, and hospital pharmacies typically procure Bevastim on a per-patient-per-cycle basis calculated from each individual patient’s body weight and assigned treatment regimen; for a 70 kg patient receiving 5 mg/kg every 2 weeks (350 mg/infusion), procurement requires 3.5 × 100 mg vials or partial use of a 400 mg vial per infusion cycle; for a 70 kg patient receiving 15 mg/kg every 3 weeks (1,050 mg/infusion), procurement requires 2 × 400 mg vials + 2.5 × 100 mg vials or 2 × 400 mg vials + 1 × 100 mg vial depending on dose rounding practice; vials are single-dose only any unused portion of a vial must be discarded per institutional waste and cytotoxic waste disposal protocols |
| Dosing Schedule | Metastatic Colorectal Cancer (mCRC) First-Line (with bolus-IFL): Bevacizumab 5 mg/kg IV every 2 weeks; continue until disease progression or unacceptable toxicity. mCRC First-Line with FOLFOX4 or Fluoropyrimidine-Irinotecan: 10 mg/kg IV every 2 weeks or 5 mg/kg every 2 weeks; or 7.5 mg/kg IV every 3 weeks with fluoropyrimidine-based regimens. mCRC Second-Line (with FOLFOX4): 10 mg/kg IV every 2 weeks. mCRC Continuation beyond First Progression (ML18147): 2.5 mg/kg per week equivalent (5 mg/kg every 2 weeks) in combination with standard second-line chemotherapy, following disease progression on a first-line bevacizumab-containing regimen. Stage III/IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer First-Line Following Surgical Resection: Bevacizumab 15 mg/kg IV every 3 weeks in combination with carboplatin and paclitaxel for up to 6 cycles, followed by bevacizumab 15 mg/kg IV every 3 weeks as single-agent maintenance until disease progression or unacceptable toxicity. Platinum-Resistant Recurrent Ovarian Cancer: Bevacizumab 10 mg/kg IV every 2 weeks in combination with paclitaxel, pegylated liposomal doxorubicin (PLD), or weekly topotecan; or 15 mg/kg IV every 3 weeks with topotecan given on a 3-weekly schedule. Platinum-Sensitive Recurrent Ovarian Cancer: Bevacizumab 15 mg/kg IV every 3 weeks in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by single-agent bevacizumab 15 mg/kg every 3 weeks until disease progression. Surgical Hold: Do not initiate bevacizumab until at least 28 days following major surgery and until the surgical incision has fully healed; withhold bevacizumab for at least 28 days prior to elective surgery. Mandatory Safety Assessments: Monitor blood pressure every 2–3 weeks; monitor urine protein by dipstick before each infusion; conduct CBC, coagulation parameters, and renal function testing at baseline and periodically during treatment. Administration Precaution: Never mix bevacizumab with dextrose (glucose) solutions; dilute only in 0.9% normal saline. |
| Primary Indications | METASTATIC COLORECTAL CANCER (mCRC) FIRST- AND SECOND-LINE:
Bevacizumab + Bolus-IFL First-Line mCRC (Study AVF2107g): Bevacizumab 5 mg/kg IV every 2 weeks in combination with irinotecan, bolus fluorouracil, and leucovorin (bolus-IFL) for previously untreated metastatic colorectal cancer (Phase III; NCT00109070; n=813; primary endpoint OS): median OS 20.3 months vs. 15.6 months (HR 0.66; 95% CI, 0.54–0.81; p<0.001); median PFS 10.6 months vs. 6.2 months (HR 0.54; 95% CI, 0.45–0.66; p<0.001); ORR 45% vs. 35% (p<0.01); median duration of response 10.4 months vs. 7.1 months; FDA approval February 26, 2004. The addition of bevacizumab to bolus-IFL chemotherapy provided a 4.7-month OS benefit in first-line mCRC the first anti-angiogenic therapy to demonstrate a statistically significant survival advantage in a solid tumor indication. In the second-line mCRC study (Study E3200; bevacizumab + FOLFOX4 vs. FOLFOX4 alone): median OS 13.0 months vs. 10.8 months (HR 0.75; 95% CI, 0.63–0.89; p=0.001); median PFS 7.3 months vs. 4.7 months; ORR 23% vs. 9%. In the continuation beyond first progression study (Study ML18147): bevacizumab + standard second-line chemotherapy vs. chemotherapy alone: median OS 11.2 months vs. 9.8 months (HR 0.81; 95% CI, 0.69–0.94; p=0.0057); median PFS 5.7 months vs. 4.0 months (HR 0.68; p<0.0001). EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER FIRST-LINE (FOLLOWING SURGICAL RESECTION): Bevacizumab + Carboplatin/Paclitaxel Stage III/IV Ovarian Cancer, First-Line (GOG-0218 / Study AVF4095g): Bevacizumab 15 mg/kg IV every 3 weeks in combination with carboplatin and paclitaxel for up to 6 cycles, followed by single-agent bevacizumab 15 mg/kg every 3 weeks as maintenance, for Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection: median PFS 14.1 months (bevacizumab initiation arm) vs. 10.3 months (chemotherapy alone arm) (HR 0.717; 95% CI, 0.625–0.824; p<0.001), representing a statistically significant improvement in the primary endpoint; bevacizumab in combination with carboplatin and paclitaxel is the first anti-angiogenic therapy approved for first-line treatment of advanced epithelial ovarian cancer following surgical resection. For platinum-resistant recurrent ovarian cancer (AURELIA trial), bevacizumab in combination with standard chemotherapy achieved median PFS of 6.7 months vs. 3.4 months with chemotherapy alone (HR 0.48; p<0.001); ORR 27.3% vs. 11.8%. Bevacizumab requires confirmation of indication-appropriate patient selection (stage, histology, treatment history, and performance status) by an experienced gynecologic oncologist before initiating therapy in ovarian cancer settings. |
| Manufacturer / Brand | Beacon Pharmaceuticals PLC, Headquartered in Bangladesh; Country of Origin: Bangladesh; Bevastim is Beacon Pharmaceuticals PLC’s branded formulation of bevacizumab concentrated solution for IV infusion in 100 mg and 400 mg vial strengths; Beacon Pharmaceuticals PLC is a Bangladesh-based pharmaceutical manufacturer producing a range of oncology, targeted therapy, biologic, and specialty medicines for domestic and international oncology markets; the active pharmaceutical ingredient bevacizumab was originally developed by Genentech (a Roche Group member) and is commercialized globally as Avastin (bevacizumab) by Roche; multiple biosimilar and branded generic formulations of bevacizumab are now manufactured worldwide; Brand: Beacon; Categories: Beacon Pharmaceuticals Medicines, Colorectal Cancer Medicines, Oncology Medicines, Ovarian Cancer Medicines |
Global Supplier: Mediaid Pharmacy Worldwide Shipping for Bevastim 100 MG & 400 MG (Bevacizumab)
Mediaid Pharmacy is a Dhaka-based supplier of specialty anti-angiogenic biologic therapies, colorectal cancer medicines, ovarian cancer medicines, and oncology biologics with worldwide shipping to patients, oncology departments, infusion units, colorectal cancer and gynecologic oncology treatment programs, hospital pharmacies, oncology day units, patient access programs, and international distributors across all regions. Bevastim 100 MG & 400 MG (Bevacizumab), manufactured by Beacon Pharmaceuticals PLC in Bangladesh, is supplied as a concentrated solution for IV infusion in single-dose sterile glass vials (100 mg/4 mL and 400 mg/16 mL), with pricing quotations, stock confirmation, full product documentation, cold-chain shipping arrangements (storage at 2–8°C), and end-to-end international delivery tracking for every order.
Bevastim (Bevacizumab) is an IV-administered oncology biologic requiring cold-chain temperature-controlled shipping (2–8°C) to maintain product integrity and biological activity throughout international transit Mediaid Pharmacy coordinates appropriate cold-chain packaging and logistics for all international bevacizumab orders based on destination country, transit time, and regulatory requirements.
Colorectal cancer treatment programs procuring bevacizumab for first- and second-line mCRC combination chemotherapy regimens; gynecologic oncology programs co-sourcing bevacizumab with carboplatin and paclitaxel for first-line advanced ovarian cancer treatment protocols; hospital formulary procurement departments sourcing Bevastim as part of targeted oncology medicines and anti-angiogenic biologic portfolios; and individual patients and families sourcing bevacizumab for metastatic colorectal cancer treatment can contact the Mediaid Pharmacy team through WhatsApp, phone, or email for Bevastim 100 MG & 400 MG stock availability, current pricing, shipping options, and international delivery timelines.
Why Choose Bevastim 100 MG & 400 MG (Bevacizumab) from Mediaid Pharmacy?
Bevastim (Bevacizumab) from Beacon Pharmaceuticals PLC delivers the validated anti-VEGF anti-angiogenic mechanism of the most broadly indicated oncology biologic in clinical practice the first targeted anti-angiogenic therapy to demonstrate a survival benefit in metastatic colorectal cancer and the first approved anti-angiogenic therapy for first-line Stage III/IV epithelial ovarian cancer following surgical resection supplied as a concentrated solution for IV infusion in 100 mg and 400 mg vial strengths, enabling flexible weight-based dosing (5, 10, and 15 mg/kg) across all approved oncology indications. Bevacizumab is pharmacologically and clinically distinguished across the anti-angiogenic oncology landscape by four evidence-based attributes.
First, bevacizumab holds the broadest indication portfolio of any anti-angiogenic biologic in oncology spanning metastatic colorectal cancer (first- and second-line, and beyond first progression), Stage III/IV epithelial ovarian/fallopian tube/primary peritoneal cancer (first-line and platinum-resistant/platinum-sensitive recurrent), non-squamous non-small cell lung cancer (NSCLC), glioblastoma, metastatic renal cell carcinoma (mRCC), and cervical cancer, making bevacizumab the single most broadly deployed anti-angiogenic therapy in solid tumor oncology globally; its multi-indication approval profile reflects VEGF-driven angiogenesis as a universal driver of tumor progression across histologically diverse solid tumor types, establishing bevacizumab as the backbone anti-angiogenic agent in combination chemotherapy regimens for a larger patient population than any other anti-angiogenic therapy currently available.
Second, bevacizumab’s survival benefit in first-line metastatic colorectal cancer remains one of the most robustly validated survival data sets in medical oncology the pivotal Study AVF2107g demonstrated a statistically significant 4.7-month improvement in median OS (20.3 months vs. 15.6 months; HR 0.66; p<0.001) and a 4.4-month improvement in median PFS (10.6 months vs. 6.2 months; HR 0.54; p<0.001) when bevacizumab was added to bolus-IFL chemotherapy; this first-line survival advantage in mCRC was subsequently confirmed across multiple additional Phase III trials (Study E3200, ML18147) and a seven-trial pooled individual patient data meta-analysis (HR for OS 0.80, 95% CI 0.71–0.90; HR for PFS 0.57, 95% CI 0.46–0.71), establishing the consistency and reproducibility of bevacizumab’s anti-tumor activity across diverse colorectal cancer patient populations, chemotherapy backbone regimens, and treatment lines.
Third, bevacizumab extends PFS in first-line advanced ovarian cancer in Study GOG-0218/AVF4095g, the addition of bevacizumab 15 mg/kg every 3 weeks to carboplatin and paclitaxel chemotherapy, followed by single-agent bevacizumab maintenance, improved median PFS from 10.3 months to 14.1 months (HR 0.717; p<0.001) in Stage III/IV epithelial ovarian cancer following initial surgical resection; in platinum-resistant recurrent ovarian cancer (AURELIA trial), bevacizumab in combination with physician’s choice chemotherapy improved median PFS from 3.4 months to 6.7 months (HR 0.48; p<0.001) with an ORR improvement from 11.8% to 27.3%, establishing bevacizumab as the standard-of-care anti-angiogenic partner across first-line, platinum-resistant, and platinum-sensitive ovarian cancer settings.
Fourth, bevacizumab’s established clinical safety profile dominated by hypertension, proteinuria, and bleeding managed with proactive monitoring, and characterized by well-defined hold/discontinue decision criteria for GI perforation, arterial thromboembolic events, wound healing complications, and RPLS enables oncology teams with structured monitoring protocols to manage bevacizumab-related toxicities and maintain treatment continuity; Grade 3 or higher hypertension occurs in approximately 11–18% of patients and is manageable with antihypertensive therapy in the majority of cases; Grade 3 proteinuria occurs in approximately 3–4% of patients; GI perforation, the most clinically critical adverse event, occurs in approximately 0.3–2.4% of patients depending on the indication and chemotherapy backbone, and risk is highest in patients with prior radiation therapy, GI surgery, or prior tumor involvement of the bowel; the well-characterized safety profile of bevacizumab, supported by over 20 years of post-marketing surveillance data, enables informed patient selection and proactive toxicity management by experienced oncology teams.
To source the complete range of anti-angiogenic oncology biologics, colorectal cancer targeted therapies, ovarian cancer medicines, and Beacon Pharmaceuticals oncology portfolio, visit the Mediaid Pharmacy colorectal cancer medicines portfolio, the ovarian cancer medicines collection, the oncology medicines collection, and the Beacon Pharmaceuticals medicines range, and contact the team for a personalized quotation and international cold-chain shipping confirmation.
Frequently Asked Questions About Bevastim 100 MG & 400 MG (Bevacizumab)
What is Bevastim 100 MG & 400 MG (Bevacizumab) used for?
Bevastim 100 MG & 400 MG (Bevacizumab) is an IV anti-VEGF anti-angiogenic biologic with approved indications spanning multiple solid tumor types. The two primary oncology indications stocked by Mediaid Pharmacy are: (1) Metastatic Colorectal Cancer (mCRC) bevacizumab in combination with intravenous fluoropyrimidine-based chemotherapy is indicated for the first- or second-line treatment of adult patients with metastatic carcinoma of the colon or rectum; in first-line mCRC (Study AVF2107g), bevacizumab + bolus-IFL achieved median OS of 20.3 months vs. 15.6 months (HR 0.66; p<0.001), median PFS of 10.6 months vs. 6.2 months (HR 0.54; p<0.001), and ORR of 45% vs. 35%; (2) Stage III or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer bevacizumab in combination with carboplatin and paclitaxel, followed by bevacizumab as single-agent maintenance, for Stage III or IV disease following initial surgical resection; in Study GOG-0218, this regimen achieved median PFS of 14.1 months vs. 10.3 months (HR 0.717; p<0.001). Additional approved indications for bevacizumab include non-squamous NSCLC (with carboplatin and paclitaxel), glioblastoma (single agent after prior therapy), metastatic renal cell carcinoma (with interferon alfa), cervical cancer (with chemotherapy), platinum-resistant recurrent ovarian cancer (with chemotherapy), and platinum-sensitive recurrent ovarian cancer (with chemotherapy). Bevastim 100 MG & 400 MG (Bevacizumab) is available through Mediaid Pharmacy with worldwide shipping to patients and metastatic colorectal cancer treatment programs globally.
What is the generic name of Bevastim?
The generic name (International Nonproprietary Name, INN) of Bevastim is bevacizumab. Bevacizumab is a recombinant humanized IgG1 monoclonal antibody that selectively binds to and neutralizes VEGF-A (vascular endothelial growth factor A), the primary ligand driving tumor-induced angiogenesis and neovascularization. Its mechanism of action high-affinity VEGF-A binding that prevents VEGF interaction with its endothelial cell receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1), thereby blocking downstream PI3K-AKT and MAPK signaling cascades that drive endothelial proliferation, migration, and new blood vessel formation targets the shared pro-angiogenic pathway present in virtually all solid tumors that have undergone the angiogenic switch (transition from avascular to vascular growth). Bevacizumab is mechanistically distinct from EGFR inhibitors (cetuximab, panitumumab, erlotinib), VEGFR tyrosine kinase inhibitors (sunitinib, sorafenib, axitinib), KRAS inhibitors (adagrasib, sotorasib), and PARP inhibitors (olaparib, niraparib) all of which target intracellular signaling nodes rather than the extracellular VEGF-A ligand directly. Bevacizumab is composed of 93% human and 7% murine antibody sequences, was derived from the murine anti-VEGF monoclonal antibody A.4.6.1, and was developed by Genentech (a Roche Group member); it is commercialized globally as Avastin by Roche; Bevastim is the branded generic formulation manufactured by Beacon Pharmaceuticals PLC in Bangladesh. Mediaid Pharmacy distributes Bevastim 100 MG 400 MG Bevacizumab globally with worldwide shipping to patients, oncology programs, and hospital pharmacies.
What are the side effects of Bevastim (Bevacizumab)?
The most clinically significant adverse reactions of bevacizumab are GI perforation, wound healing complications, severe hemorrhage, arterial thromboembolic events (ATEs), venous thromboembolic events (VTEs), hypertensive crisis, nephrotic syndrome, and reversible posterior leukoencephalopathy syndrome (RPLS). Gastrointestinal Perforation and Fistula: GI perforation occurs in 0.3–2.4% of patients depending on indication; permanently discontinue bevacizumab in patients who develop GI perforation or fistula. Wound Healing Complications: bevacizumab impairs wound healing; do not initiate until at least 28 days following major surgery; withhold bevacizumab for at least 28 days prior to elective surgery; permanently discontinue in patients with wound dehiscence. Hemorrhage: severe or fatal pulmonary hemorrhage (hemoptysis) occurs in up to 31% of patients with squamous NSCLC bevacizumab is contraindicated in squamous NSCLC; Grade 3–5 hemorrhagic events occur across all indications; permanently discontinue for severe bleeding. Arterial Thromboembolic Events (ATEs): stroke, TIA, myocardial infarction, and angina have been reported; permanently discontinue for any ATE; risk is higher in patients aged ≥65 years and those with prior history of ATEs. Hypertension: Grade 3 or higher hypertension in 11–18% of patients; monitor blood pressure every 2–3 weeks; initiate or intensify antihypertensive treatment; withhold for uncontrolled hypertension; permanently discontinue for hypertensive crisis. Proteinuria and Nephrotic Syndrome: monitor by dipstick urinalysis before each infusion; withhold for proteinuria ≥2+ dipstick; monitor 24-hour urine protein; permanently discontinue for nephrotic syndrome (proteinuria >3.5 g/24 hours). RPLS: permanently discontinue bevacizumab if RPLS is confirmed. Infusion-Related Reactions: decrease infusion rate; permanently discontinue for severe reactions. Ovarian Failure: premature ovarian failure reported in premenopausal women counsel patients prior to initiation. Most Common (≥10%) Adverse Reactions: hypertension, fatigue, epistaxis (nosebleed), headache, rhinitis, proteinuria, diarrhea, nausea, stomatitis, dyspnea, dermatitis, and leukopenia. All patients initiating Bevastim (Bevacizumab) should have baseline blood pressure, urine protein, CBC, coagulation parameters, and renal function assessed, and treatment initiated under the supervision of a qualified oncologist experienced in managing anti-angiogenic biologic toxicities.
How effective is Bevastim (Bevacizumab) for metastatic colorectal cancer?
Bevacizumab demonstrated clinically meaningful and statistically significant improvements in overall survival, progression-free survival, and overall response rate across multiple Phase III registration and confirmatory trials in metastatic colorectal cancer. Study AVF2107g First-Line mCRC (Phase III; n=813; bevacizumab + bolus-IFL vs. placebo + bolus-IFL; primary endpoint OS): median OS 20.3 months vs. 15.6 months (HR 0.66; 95% CI, 0.54–0.81; p<0.001); median PFS 10.6 months vs. 6.2 months (HR 0.54; 95% CI, 0.45–0.66; p<0.001); ORR 45% vs. 35% (p<0.01); median duration of response 10.4 months vs. 7.1 months representing a 4.7-month OS gain and a landmark survival achievement as the first anti-angiogenic therapy to demonstrate a survival benefit in any solid tumor. Study E3200 Second-Line mCRC (Phase III; n=829; bevacizumab + FOLFOX4 vs. FOLFOX4 alone vs. bevacizumab alone): median OS 13.0 months vs. 10.8 months (HR 0.75; 95% CI, 0.63–0.89; p=0.001); median PFS 7.3 months vs. 4.7 months; ORR 23% vs. 9% confirming bevacizumab activity in the second-line mCRC setting. Study ML18147 Continuation Beyond First Progression (Phase III; n=820; bevacizumab + second-line chemotherapy vs. second-line chemotherapy alone after first-line bevacizumab-containing regimen): median OS 11.2 months vs. 9.8 months (HR 0.81; 95% CI, 0.69–0.94; p=0.0057); median PFS 5.7 months vs. 4.0 months (HR 0.68; p<0.0001) establishing the clinical benefit of continuing bevacizumab beyond first progression. Seven-Trial Pooled Individual Patient Data Meta-Analysis (N=3,742): addition of bevacizumab to chemotherapy: OS HR 0.80 (95% CI, 0.71–0.90); PFS HR 0.57 (95% CI, 0.46–0.71) confirming the survival and PFS benefit across multiple chemotherapy backbones, treatment lines, and colorectal cancer patient populations. Bevastim 100 MG & 400 MG (Bevacizumab) is available through Mediaid Pharmacy; visit the colorectal cancer medicines collection and oncology medicines collection for the complete anti-angiogenic therapy portfolio.
What is the difference between Bevastim 100 MG and Bevastim 400 MG (Bevacizumab)?
Bevastim 100 MG and Bevastim 400 MG are the same active pharmaceutical ingredient (bevacizumab) at the same concentration (25 mg/mL) in two different total volume vial sizes, designed to facilitate weight-based dose preparation across the full range of clinical dosing schedules for all approved bevacizumab indications. Bevastim 100 MG: 100 mg bevacizumab in 4 mL concentrated solution (25 mg/mL) per single-dose sterile glass vial, 1 vial per box; suitable for lower-weight patients or for supplementary vials needed to reach exact weight-based target doses when combined with 400 mg vials; also used for lower-dose schedules (5 mg/kg every 2 weeks in lighter patients). Bevastim 400 MG: 400 mg bevacizumab in 16 mL concentrated solution (25 mg/mL) per single-dose sterile glass vial, 1 vial per box; suitable for heavier patients and higher-dose schedules (10–15 mg/kg per infusion); reduces the number of vials required per infusion cycle for patients in the typical adult weight range (60–90 kg) on 10 or 15 mg/kg dosing schedules; more cost-efficient for high-dose regimens in terms of vials required per infusion. Dose Preparation Guidance: both vial sizes are diluted in 0.9% normal saline (100 mL total volume); institutional pharmacy teams typically combine both vial strengths to achieve exact patient weight-based dose targets; vials are single-dose only any unused product must be discarded per cytotoxic waste protocols; do not pool, re-dilute, or re-use opened vials. For the complete bevacizumab portfolio including both vial strengths, visit the Mediaid Pharmacy oncology medicines collection and Beacon Pharmaceuticals medicines range.
Is Bevastim (Bevacizumab) safe during pregnancy or while breastfeeding?
Bevastim (Bevacizumab) can cause fetal harm based on its mechanism of action and nonclinical animal reproductive toxicology findings bevacizumab should not be used during pregnancy. VEGF-A inhibition and anti-angiogenic suppression of vascular development is expected to disrupt critical embryonic and fetal developmental processes dependent on angiogenesis, including placentation, organogenesis, fetal vascularization, and fetal growth; in animal reproductive toxicology studies, IV administration of bevacizumab to pregnant rabbits every 3 days during organogenesis at approximately 1–10 times the clinical dose of 10 mg/kg produced fetal resorptions, decreased maternal and fetal body weight gain, and increased gross and skeletal fetal abnormalities, confirming the embryotoxic and fetotoxic potential of bevacizumab at clinically relevant exposures. Limited postmarketing reports describe cases of fetal malformations with bevacizumab use in pregnancy; however, these reports are insufficient to determine drug-associated risks precisely. Contraception requirement: females of reproductive potential must use effective contraception during bevacizumab treatment and for a minimum of 6 months after the last dose, reflecting bevacizumab’s long plasma half-life of approximately 20 days (range 11–50 days); verify pregnancy status with a pregnancy test before initiating Bevastim in all females of reproductive potential. Breastfeeding: no data are available on the presence of bevacizumab in human milk or its effects on the breastfed infant or milk production; however, human IgG antibodies are present in human milk; because of the potential for serious adverse reactions from bevacizumab in breastfed infants, breastfeeding is not recommended during bevacizumab treatment and for at least 6 months after the last dose. Ovarian Failure and Fertility: bevacizumab treatment has been associated with premature ovarian failure (POF) in premenopausal women receiving bevacizumab; some cases of POF are reversible after bevacizumab discontinuation but persistent POF has also been reported; prior to initiating therapy, inform premenopausal female patients of the potential risk of ovarian failure and its impact on fertility, and discuss fertility preservation options with the treating oncologist before starting bevacizumab. All aspects of reproductive planning, contraceptive requirements, and fertility counseling should be discussed with the treating oncologist before initiating bevacizumab therapy.
Can I order Bevastim 100 MG & 400 MG (Bevacizumab) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Bevastim 100 MG & 400 MG (Bevacizumab), concentrated solution for IV infusion, 1 vial per box, manufactured by Beacon Pharmaceuticals PLC in Bangladesh, to patients, colorectal cancer and gynecologic oncology departments, bevacizumab-based chemotherapy treatment programs, hospital pharmacies, oncology day units, patient access programs, and healthcare providers globally. Bevastim (Bevacizumab) requires cold-chain temperature-controlled shipping (storage at 2–8°C/36–46°F) to maintain biologic activity and product integrity throughout international transit Mediaid Pharmacy coordinates appropriate cold-chain packaging and logistics for all international bevacizumab orders, with shipping methods and packaging validated for destination country, transit time, and regulatory requirements. Contact Mediaid Pharmacy via WhatsApp, phone, or email at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability for both 100 MG and 400 MG vial sizes, cold-chain shipping options, and international delivery details for your country. Prescription documentation and applicable regulatory import/export requirements must be met for bevacizumab dispensing in accordance with country-specific regulations. For the complete portfolio of Beacon Pharmaceuticals medicines available with worldwide shipping, visit the Mediaid Pharmacy Beacon Pharmaceuticals medicines page.
Order Bevastim 100 MG & 400 MG (Bevacizumab) with Worldwide Shipping
Phone / WhatsApp: +8801773428128 | Email: info@mediaidpharmacy.com




Reviews
There are no reviews yet.